Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
HLCM051eNK® cells AKT-01/HLCN061
Applicable field (uses covered by this announcement)
Acute respiratory distress syndrome (ARDS)Acute phase of cerebral infarctionTrauma-induced acute kidney injury (AKI)Solid tumorsOphthalmologyLiver disease
Launch date1 November 2026 (scheduled establishment date of the Account Management Department)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | HLCM051, eNK® cells AKT-01/HLCN061 |
| Launch date | 1 November 2026 (scheduled establishment date of the Account Management Department) |
| Applicable area | Acute respiratory distress syndrome (ARDS), Acute phase of cerebral infarction, Trauma-induced acute kidney injury (AKI), Solid tumors, Ophthalmology, Liver disease |
Items this document does not state (15)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strategically manage medium- to long-term relationships with customers in anticipation of future product launches, including supporting product adoption at medical institutions, helping establish operational systems for administration within hospitals, promoting appropriate use, and coordinating with healthcare professionals from multiple disciplines.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.